Vincerx Pharma Inc's Customers Performance

Name: Vincerx Pharma Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

VINC

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


VINC's Source of Revenues		• List of VINC Customers

for the same period Vincerx Pharma Inc

• List of VINC Customers

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Vincerx Pharma Inc's Comment on Sales, Marketing and Customers

News about Vincerx Pharma Inc Contracts

Promising Advances in Cancer Therapeutics: Vincerx Pharma's Groundbreaking Research

presents exciting developments in the field of cancer therapeutics with Vincerx Pharma s groundbreaking research. The company s presentations at the American Association for Cancer Research (AACR) Annual Meeting 2024 and ASH 2023 have demonstrated positive preliminary data and highlighted the significant potential of their innovative compounds in combatting metastatic solid tumors.Vincerx Pharma, a leader in precision oncology, recently presented positive preliminary Phase 1 data for their novel compound, VIP236, at the AACR Annual Meeting 2024. This groundbreaking drug has shown remarkable clinical activity, including tumor reduction, and an improved safety profile in heavily pretreated patients with metas...

Vincerx Pharma Presents Positive Phase 1 Results for VIP236 at AACR and Provides Promising Pipeline Updates at Virtual Investor Event

The American Association for Cancer Research (AACR) Annual Meeting in 2024 hosted a significant event for Vincerx Pharma Inc, as the company presented preliminary Phase 1 data for their promising drug candidate, VIP236. Additionally, Vincerx took this opportunity to provide updates on the progress of their pipeline, including insights into the VIP943 program. This article will delve into the key findings from the virtual investor event and shed light on the future prospects of Vincerx Pharma.Phase 1 VIP236 Data Presented at AACR:The virtual investor event organized by Vincerx Pharma focused on their investigational drug candidate, VIP236. The preliminary Phase 1 data presented at the AACR Annual Meeting demo...

Revolutionary ADC Therapy VIP943 Unveiled: Vincerx Pharma Paves the Way to Precise and Safe Cancer Treatment

Introduction
In an exciting development for the field of oncology, Vincerx Pharma Inc. presented its latest preclinical findings at the prestigious ASH 2023 conference. The company s VersAptx platform, known for its cutting-edge antibody-drug conjugate (ADC) technology, took center stage with the unveiling of the novel CD123-targeted ADC, VIP943. The poster presentation showcased the remarkable selectivity, activity, and safety of VIP943, offering new hope in the fight against cancer.
Vincerx Pharma Inc.: A Leader in Precision Medicine
Vincerx Pharma Inc. is an innovative biopharmaceutical company with a strong focus on precision medicine. Leveraging its extensive expertise in ADC developmen...

VINC's Stock Performance relative to it's Customers

VINC's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Vincerx Pharma Inc	0.05	0.00	-22.65	12
SUBTOTAL	0.00	0.00	0.00	-

Sources: Vincerx Pharma Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Vincerx Pharma Inc’s corporate clients.
For your research, we’ve provided 9 tables on Vincerx Pharma Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.